Metabolic interaction between amino acid deprivation and cisplatin synergistically reduces phosphoribosyl-pyrophosphate and augments cisplatin cytotoxicity.

Scientific Reports
Nisreen WahwahGerry R Boss

Abstract

Cisplatin is a mainstay of cancer chemotherapy. It forms DNA adducts, thereby activating poly(ADP-ribose) polymerases (PARPs) to initiate DNA repair. The PARP substrate NAD+ is synthesized from 5-phosphoribose-1-pyrophosphate (PRPP), and we found that treating cells for 6 h with cisplatin reduced intracellular PRPP availability. The decrease in PRPP was likely from (1) increased PRPP consumption, because cisplatin increased protein PARylation and PARP1 shRNA knock-down returned PRPP towards normal, and (2) decreased intracellular phosphate, which down-regulated PRPP synthetase activity. Depriving cells of a single essential amino acid decreased PRPP synthetase activity with a half-life of ~ 8 h, and combining cisplatin and amino acid deprivation synergistically reduced intracellular PRPP. PRPP is a rate-limiting substrate for purine nucleotide synthesis, and cisplatin inhibited de novo purine synthesis and DNA synthesis, with amino acid deprivation augmenting cisplatin's effects. Amino acid deprivation enhanced cisplatin's cytotoxicity, increasing cellular apoptosis and DNA strand breaks in vitro, and intermittent deprivation of lysine combined with a sub-therapeutic dose of cisplatin inhibited growth of ectopic hepatomas in mi...Continue Reading

References

Jan 1, 1977·Medical and Pediatric Oncology·B JonesN Hakami
Jan 1, 1986·Cancer Investigation·L E Damon, E C Cadman
Feb 15, 1987·Analytical Biochemistry·P P Van Veldhoven, G P Mannaerts
Jun 1, 1973·Analytical Biochemistry·C Bernofsky, M Swan
Jun 1, 1970·Hoppe-Seyler's Zeitschrift für physiologische Chemie·K Brand, K Deckner
Apr 1, 1993·Carcinogenesis·A BürkleW J Zeller
May 5, 1999·Acta Oncologica·A Johnsson, J Wennerberg
Apr 30, 2008·Nutrition and Cancer·Xavier DurandoPhilippe Chollet
Mar 31, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Evan S GlazerFrancesco Izzo
Sep 6, 2011·Oncogene·L GalluzziG Kroemer
Dec 17, 2011·Expert Opinion on Biological Therapy·Vaidehi AgrawalArthur E Frankel
Mar 7, 2012·Genes & Development·Xin Luo, W Lee Kraus
Jun 21, 2012·Nature Reviews. Molecular Cell Biology·Bryan A Gibson, W Lee Kraus
Aug 7, 2012·Investigational New Drugs·Patrick A OttJedd D Wolchok
Feb 12, 2013·Methods in Molecular Biology·Francis Ka-Ming ChanMaría José De Rosa
Apr 5, 2014·Trends in Cell Biology·Liron Bar-Peled, David M Sabatini
Jul 25, 2014·European Journal of Pharmacology·Shaloam Dasari, Paul Bernard Tchounwou
Mar 6, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benjamin K TomlinsonPrimo N Lara
Sep 3, 2016·Journal of Cell Science·Alasdair R GunnNicholas D Lakin
Feb 9, 2017·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Min HeYi-Ping You
Jul 29, 2017·Journal of Hematology & Oncology·Marcus Kwong Lam Fung, Godfrey Chi-Fung Chan

❮ Previous
Next ❯

Methods Mentioned

BETA
nucleotide exchange
PARylation
xenograft

Software Mentioned

Image
GraphPad Prism

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Related Papers

Microbiology and Molecular Biology Reviews : MMBR
B Hove-JensenMartin Willemoës
Ryōikibetsu shōkōgun shirīzu
H Imaeda, Y Wada
Nihon rinsho. Japanese journal of clinical medicine
Kaname Kawasugi, Fujio Takeuchi
© 2021 Meta ULC. All rights reserved